Comparative Pharmacology
Head-to-head clinical analysis: CANDEX versus EXSEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDEX versus EXSEL.
CANDEX vs EXSEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Adults: 150 mg orally once daily
1-2 mg orally once daily; maximum dose 2 mg/day.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Category C
Category C
Topical Antifungal and Corticosteroid
Topical Antifungal